home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

An Introduction to FDA's Regulation of Over-the-Counter (OTC) Drug Products

 
  July 26, 2013  
     
 
ComplianceOnline, Online Event
2013-08-07


Why Should You Attend:

All OTC drugs are regulated by the U.S. Food and Drug Administration’s (“FDA”) and can enter the market in one of the following ways: (a) by complying with an applicable monograph; (b) as the subject of an FDA approved New Drug Application; or (c) via an FDA approved Rx-to-OTC Switch.

Most of the OTC drugs available today are marketed and sold as OTC monograph drug products. Although still a very, very small percentage of the total number of OTC drug products on the market, the Rx-to-OTC Switch regulatory pathway is becoming increasingly popular for placing OTC drugs on the shelves as companies look for ways to extend the life cycle of their branded prescription products.

This webinar will provide beginners with an introduction to FDA’s regulation of OTC drug products. Some of the topics to be covered in this webinar include:

  • Whether a drug product can be marketed and sold as an OTC
  • The various pathways for bringing an OTC drug to market
  • The OTC Monograph process and the products currently covered by monographs
  • Switching an Rx drug product to an OTC
  • Rules for labeling and marketing an OTC drug product, and
  • Strategies for mitigating potential FDA regulatory risks based on recent Agency enforcement action.

Learning Objectives:

  • Gain a basic understanding of FDA's regulation of OTC Drug Products.
  • Learn to distinguish between the various regulatory pathways for bringing an OTC drug to market.
  • Understand how to use an OTC monograph and the various categories of drugs covered by them.
  • Have a working knowledge of the Rx-to-OTC Switch option for bringing an OTC drug to market.
  • Be able to identify the primary required elements of an OTC drug label.
  • Recognize potential marketing and promotional risks.

Areas Covered in the Seminar:

  • FDA's regulation of over-the-counter drug products or OTC drugs.
  • Bringing an OTC drug to market under an OTC monograph.
  • Where to find FDA's list of existing monographs and identification of the various product categories covered by monographs.
  • An introduction to FDA's Rx-to-OTC Switch procedures and the benefits / challenges of pursuing such an option.
  • Labeling an OTC drug product.
  • Potential FDA enforcement risks.
 
 
Organized by: ComplianceOnline
Invited Speakers: Karl Nobert, is a food and drug regulatory attorney with the law firm of Squire Sanders in Washington, DC. He provides regulatory advice and counseling to domestic and international pharmaceutical, OTC and consumer product companies on issues related to the U.S. Food and Drug Administration’s regulation of the manufacture, labeling, distribution, marketing and sale of drugs, dietary supplements, devices and food. He regularly works with companies on labeling and marketing compliance; provides counseling to clients during FDA enforcement proceedings; and supports due diligence efforts related to product line and company acquisitions in the pharmaceutical, OTC drug and dietary supplement sectors.
 
Deadline for Abstracts: 2013-08-07
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702356?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.